clonidine has been researched along with sb 203580 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beitz, AJ; Kim, SJ; Lee, JH; Oh, SB; Roh, DH; Yeo, JH; Yoon, SY | 1 |
1 other study(ies) available for clonidine and sb 203580
Article | Year |
---|---|
Clonidine, an alpha-2 adrenoceptor agonist relieves mechanical allodynia in oxaliplatin-induced neuropathic mice; potentiation by spinal p38 MAPK inhibition without motor dysfunction and hypotension.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antineoplastic Agents; Blood Pressure; Clonidine; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Hyperalgesia; Imidazoles; Male; Mice; Motor Activity; Organoplatinum Compounds; Oxaliplatin; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Spinal Cord; Spinal Cord Dorsal Horn | 2016 |